Clinical Trial Update: A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating amivantamab plus mFOLFOX6 or FOLFIRI versus cetuximab plus mFOLFOX6 or FOLFIRI as first-line therapy in KRAS/NRAS and BRAF wild-type un…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Amivantamab (amivantamab)
• Cetuximab (cetuximab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Colorectal Neoplasms | Phase 3 | Status: RECRUITING